AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deSEP 242 min read$OSTX

OS Therapies: OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)

OS Therapies (NYSE American: OSTX) announced that the World Health Organization approved 'Herlystic' as the brand name for OST-HER2, a gene-edited cancer immunotherapy. The company plans to initiate regulatory submissions for early market access in the U.K., U.S., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, and the company aims to file for a Biologics License Application in the U.S. in 2026.

Original reporting
finanznachrichten.de
Published Sep 24, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 24, 2026, 1:42 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefRegulation
Primary signal
$OSTX
Bullish
high confidence
Mentioned
$OSTX
Relevance
8/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$OSTXBullishMed
01

Why it matters

The approval removes a branding barrier, allowing the company to pursue accelerated regulatory pathways and potential PRV sales, which could materially affect valuation.

02

Market read

First‑time disclosure of WHO brand name approval creates a new catalyst for OSTX, potentially driving short‑term price movement and long‑term valuation.

03

What to watch

Potential competition from other HER2 therapies and the need for robust Phase 3 data.

Relevance 8/10Novelty 8/10Timing: today

Background

OS Therapies announced WHO brand name approval for its lead asset OST-HER2 and outlined upcoming submissions to MHRA, FDA, EMA, and TGA.

Company-level read

Ticker impact

$OSTXBullishHigh confidence
Context

WHO approved the brand name 'Herlystic' for OST-HER2, enabling OS Therapies to begin international regulatory submissions.

Expected impact

Modest short‑term rally on news, with larger upside if filings succeed.

Evidence & confidence

First disclosure of brand name approval and clear regulatory roadmap creates new catalyst for the stock.

Market effects

Sector

Highlights progress in gene‑edited Listeria immunotherapy, may boost biotech sector sentiment.

Regional

UK and US regulatory activity could attract investor interest in those markets.

Global

WHO brand name approval is globally relevant for oncology drug pipelines.

Counterpoint

What could challenge this read

Regulatory hurdles remain; early filings do not guarantee approval, risk of delays.

Key entities

  • company
    OS Therapies, Inc.

    Clinical‑stage oncology company developing gene‑edited Listeria‑based immunotherapies.

  • regulatory_body
    World Health Organization

    International health agency that approved the brand name.

Read at source← All news

Related articles

OCT 6
$OSTXMedAI 8/10

OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

OS Therapies (NYSE American: OSTX) reported a 72.7% 3-year overall survival rate for OST-HER2-treated patients in its Phase 2b trial, compared to 45.8% in historical controls. The company plans to submit regulatory applications for early market access in the U.S., U.K., Europe, and Australia. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

finance.yahoo.com2 min
OCT 1
$OSTXLow

OS Therapies: OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer

OS Therapies (NYSE American: OSTX) appointed Kerry Clem as CCO and Frank Knuettel II as CFO. Clem will lead commercialization of Herlystic, their lead immunotherapy for osteosarcoma, with U.S. launch planned post-FDA approval. Knuettel brings financial expertise. The company anticipates regulatory filings in Q4 2026 and has received tax credits for R&D.

finanznachrichten.de2 min
SEP 21
$OSTXMedAI 8/10

OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis

OS Therapies (OSTX) updated its global regulatory coordination for OST-HER2 under Project Orbis. The U.K.'s MHRA will lead the process, with a Phase 3 trial set to begin in mid-2026. The FDA aligned on the study design, and the company aims to submit a CMAA soon. OST-HER2 has received multiple designations from the FDA, EMA, and MHRA.

intelligencer.ca2 min
SEP 17
$OSTXMedAI 8/10

OS Therapies: OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program

OS Therapies (OSTX) aligned with the FDA on its Phase 3 trial design for OST-HER2, a treatment for metastatic osteosarcoma. The company will join Project Orbis, a global regulatory initiative, and aims to submit a BLA in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, and a successful BLA could make the company eligible for a Priority Review Voucher.

finanznachrichten.de2 min
SEP 15
$OSTXHighAI 8/10

OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing

OS Therapies (OSTX) announced full alignment with UK MHRA and EU EMA for its Conditional Marketing Authorisation Application (CMAA) for OST-HER2. The company expects to submit the CMAA soon and begin a confirmatory Phase 3 trial in Q4 2026. OST-HER2 has received multiple designations from the FDA and EMA, including Orphan Drug and Fast Track.

intelligencer.ca2 min